Anand Mehta, MD
Endocrinology, Diabetes & Metabolism · San Francisco, CANPI 1992902605
Payments from drug & device makers
Across 62 payments — averaging $4021.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$143K
- Eli Lilly$62K
- Vanda Pharmaceuticals Inc.$14K
- Merck$14K
- Sanofi-aventis U.S. LLC$13K
- Biohaven Pharmaceuticals, Inc.$3K
- plus $83 from 2 others
Across 2 payments — averaging $349.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biohaven Pharmaceuticals, Inc.$500
- Eli Lilly$199
What the payments were for
- Food & beverage$83100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 34 | $143,334 |
| Eli Lilly | 11 | $61,817 |
| Vanda Pharmaceuticals Inc. | 3 | $13,640 |
| Merck | 2 | $13,500 |
| Sanofi-aventis U.S. LLC | 5 | $13,494 |
| Biohaven Pharmaceuticals, Inc. | 5 | $3,441 |
| GSK | 1 | $65 |
| Daiichi Sankyo Inc. | 1 | $17 |
How this compares
$249,309 in reported general payments places this provider in the 90th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ForteoTeriparatide | 36 | $149,762 |
| TrulicityDulaglutide | 64 | $125,886 |
| OzempicSemaglutide | 63 | $101,539 |
| Teriparatide | 37 | $85,827 |
| JardianceEmpagliflozin | 66 | $73,733 |
| MounjaroTirzepatide | 38 | $57,971 |
| Evenity (2 Syringes)Romosozumab-Aqqg | 18 | $46,422 |
| RybelsusSemaglutide | 21 | $38,432 |
| ProliaDenosumab | 13 | $21,615 |
| Tresiba Flextouch U-200Insulin Degludec | 13 | $11,484 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 26 | $10,395 |
| Novolog FlexpenInsulin Aspart | 31 | $8,606 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 46 | $5,913 |
| Humalog Kwikpen U-100Insulin Lispro | 26 | $4,584 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 31 | $3,766 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in San Francisco
- Marc HellersteinSan Francisco$1.2M
- Edward HsiaoSan Francisco$766K
- Cheng Yang TuanSan Francisco$568K
- Jerrold OlefskySan Diego$26.5M
- Mark ChristiansenWalnut Creek$22.9M
- Timothy BaileyEscondido$22.3M
- Stanley HsiaLos Angeles$19.8M
- Juan FriasSan Diego$14.1M
- Paul NorwoodFresno$6.2M
- Athena Philis-Tsimikasla Jolla$6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.